azacitidine has been researched along with Androgen-Independent Prostatic Cancer in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barros-Silva, D; Carneiro, I; Carvalho, AL; Costa-Pinheiro, P; Duarte, H; Evangelista, AF; Graça, I; Henrique, R; Jerónimo, C; Marques, MM; Martins, AT; Oliveira, J; Sousa, EJ | 1 |
| Fialova, B; Kolar, Z; Langova, K; Paskova, L; Smesny Trtkova, K | 1 |
| Gao, H; Gu, J; Ren, L; Wang, X; Zhang, Y | 1 |
| Gordian, E; Quintero, C; Ramachandran, K; Reis, IM; Singal, R; Zhao, W | 1 |
| Fialova, B; Gursky, J; Kolar, Z; Langova, K; Luzna, P; Trtkova, KS | 1 |
1 trial(s) available for azacitidine and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle Proteins; DNA Methylation; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasm Metastasis; Nuclear Proteins; Prednisone; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
4 other study(ies) available for azacitidine and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis.
Topics: Aged; Azacitidine; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cohort Studies; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Regulatory Networks; Humans; Male; MicroRNAs; Middle Aged; Phenotype; Promoter Regions, Genetic; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-myc; Response Elements; RNA, Messenger; Signal Transduction; Up-Regulation | 2018 |
Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Topics: 5' Untranslated Regions; Acetylation; Androgens; Azacitidine; Butyric Acid; Cell Line, Tumor; Cell Survival; Decitabine; DNA; DNA Methylation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Male; Methyltransferases; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2013 |
Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.
Topics: Animals; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; Decitabine; Disease Progression; DNA Methylation; Humans; Male; Methyltransferases; Mice; MicroRNAs; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays | 2014 |
Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
Topics: Azacitidine; Butyric Acid; Cell Line, Tumor; Decitabine; DNA Methylation; Epigenomics; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2016 |